Table 2 |
|||||
|
Immunophenotype of Adenoid Basal Lesions. |
|||||
|
Antibody |
Number of cases tested |
Number positive |
Percentage positive |
Morphologic component positive |
Reference(s) |
|
|
|||||
|
EMA |
14 |
14 |
100 |
Peri-luminary cells |
9,20 |
|
CD10 |
1 |
1 |
100 |
All |
1 |
|
ER** |
2 |
1 |
50 |
All |
1,11 |
|
PR** |
2 |
1 |
50 |
All |
1,11 |
|
p16 |
11 |
11 |
100 |
All |
1,3 |
|
Bcl-2 |
2 |
2 |
100 |
Basaloid cells and peri-luminary cells |
1,6 |
|
CEA |
17 |
12 |
71 |
Peri-luminary cells and squamous areas |
1,9,11,14,20 |
|
CAM5.2* |
9 |
8 |
89 |
All |
9 |
|
Ki-67 |
7 |
7 |
100 |
2% positive index [6]; Majority of tumor cells positive [11]; 5–50% of basaloid cells positive [8] |
6,8,11 |
|
MNF116 |
9 |
9 |
100 |
All |
9 |
|
CK7 |
13 |
7 |
54 |
Basaloid cells and peri-luminary cells |
2,6,9,11 |
|
CK8 |
4 |
4 |
100 |
Basaloid cells and peri-luminary cells |
2,6,11 |
|
CK10 |
1 |
1 |
100 |
Squamous cells |
11 |
|
CK13 |
1 |
1 |
100 |
Squamous cells |
11 |
|
CK14 |
2 |
2 |
100 |
Basaloid cells [11] and other "scattered cells" [6] |
6,11 |
|
CK17 |
1 |
1 |
100 |
Basaloid cells |
11 |
|
CK18 |
1 |
1 |
100 |
Basaloid cells and periluminary cells |
11 |
|
CK19 |
1 |
1 |
100 |
Basaloid cells and peri-luminary cells |
11 |
|
CK20 |
9 |
1 |
11 |
NS |
9 |
|
AE1/AE3 |
6 |
6 |
100 |
All |
6,20 |
|
CK902 |
5 |
5 |
100 |
All |
20 |
|
α-SMA |
2 |
0 |
0 |
NA |
6,11 |
|
MSA |
9 |
1 |
0 |
Transitional areas between a combined ABC and ACC |
9 |
|
Laminin |
10 |
1 |
10 |
Basement membrane-like material |
6,9 |
|
Type IV collagen |
10 |
1 |
10 |
Basement membrane-like material |
6,9 |
|
S100 |
16 |
3 |
19 |
NS |
6,9,11,20 |
|
CA125 |
1 |
0 |
0 |
NA |
11 |
|
P53 |
6 |
6 |
100 |
NS |
11,13 |
|
P63 |
6 |
6 |
100 |
All: reduction of staining in squamous areas and "adenoid" areas |
1,8 |
|
|
|||||
|
ABC: adenoid basal carcinoma; ACC adenoid cystic carcinoma; ER: estrogen receptor; PR progesterone receptor; CEA carcinoembryonic antigen; CK cytokeratin; EMA epithelial membrane antigen; NA not applicable; SMA smooth muscle actin; MSA muscle specific actin; NS not stated.** stromal cells only were positive for ER and PR in one case [11]. *Cases reported by Brainard and Hart [10] are excluded because it is not clearly stated how many cases were tested. |
|||||
|
Russell and Fadare Diagnostic Pathology 2006 1:18 doi:10.1186/1746-1596-1-18 |
|||||
